Breaking Finance News

A statement released earlier today by Zacks Investment Research about Ascendis Pharma A S (NASDAQ:ASND) bumps the target price to $22.00

Just yesterday Ascendis Pharma A S (NASDAQ:ASND) traded 0.40% higher at $19.99. Ascendis Pharma A S’s 50-day moving average is $19.16 and its 200-day moving average is $16.12. The last stock price is up 23.97% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 12,167 shares of ASND traded hands, down from an average trading volume of 52,084

Zacks Investment Research upped the price target of Ascendis Pharma A S (NASDAQ:ASND) to $22.00 indicating a possible upside of 0.10%.

Recent Performance Chart

Ascendis Pharma A S (NASDAQ:ASND)

Ascendis Pharma A S has 52 week low of $11.92 and a 52 week high of $21.70 and has a market capitalization of $0.

Brief Synopsis On Ascendis Pharma A S (NASDAQ:ASND)

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company's subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma and Endocrinology Division A/S (Denmark).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *